Concord Biotech Limited CONCORDBIO NIFTY_SMALLNSEPHARMA

Healthcare · Biotechnology · India

https://www.concordbiotech.com

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Market & Price

Market Cap

₹10,997.26 Cr

Current Price

₹1,051.20

High / Low (52W)

₹2,116.90 / ₹1,014.80

Beta

0.64

Valuation

Stock P/E

42.37

Industry PE

37.60

Forward P/E

27.81

PEG Ratio

Book Value

₹173.32

Price to Book

6.07

P/S

9.49

EV/EBITDA

25.09

Dividend Yield

1.02%

Profitability & Returns

ROCE

26.76%

ROE

ROA

Profit Margin

26.97%

Op Margin

28.88%

EPS (Latest Qtr)

₹6.08

EPS (TTM)

₹24.81

Balance Sheet & Liquidity

Debt/Equity

0.09

Quick Ratio

Current Ratio

Debt

₹1.61 Cr

Total Assets

₹2,034.25 Cr

Current Assets

₹1,135.24 Cr

Working Capital

₹951.18 Cr

Ownership

Promoter Holding

74.26%

Chg in Prom Hold

FII / Inst Holding

12.54%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹10,817.26 Cr

Total Revenue (TTM)

₹1,158.69 Cr

EBITDA

₹431.08 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹10.46 Cr

Gross Margin

63.91%

Payout Ratio

43.18%

Growth (CAGR)

Revenue 5Y

18.53%

Profit 5Y

28.55%

Revenue (YoY)

13.70%

Earnings (YoY)

-16.30%

PROS

Healthy ROCE of 26.8%.
Excellent profit margin of 27.0%.
Compounding revenue at 18.5% over 5 years.
Profit CAGR of 28.6% over 5 years.

CONS

Trading 50.3% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CONCORDBIO Concord Biotech Limited NIFTY_SMALLNSEPHARMA	1,051.20	42.37	₹10,997.26 Cr	1.02%	26.76%	-	18.53%	28.55%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	-	244.22 Cr	409.61 Cr	203.99 Cr	247.06 Cr	277.77 Cr
Cost of Revenue	-	52.40 Cr	140.69 Cr	45.10 Cr	49.02 Cr	65.73 Cr
Gross Profit	-	191.82 Cr	268.92 Cr	158.88 Cr	198.04 Cr	212.03 Cr
Operating Expenses	-	107.13 Cr	81.73 Cr	115.26 Cr	127.94 Cr	131.80 Cr
Operating Income	-	84.69 Cr	187.19 Cr	43.62 Cr	70.10 Cr	80.23 Cr
EBITDA	-	114.51 Cr	198.26 Cr	76.57 Cr	104.13 Cr	104.98 Cr
Interest Expense	-	9.74 L	9.55 L	5.86 L	5.91 L	8.15 L
Pretax Income	-	101.15 Cr	183.54 Cr	58.73 Cr	85.68 Cr	86.16 Cr
Tax Provision	-	25.23 Cr	43.16 Cr	14.67 Cr	22.62 Cr	22.51 Cr
Net Income	-	75.92 Cr	140.39 Cr	44.06 Cr	63.06 Cr	63.64 Cr
Diluted EPS	9.15	7.26	-	4.21	6.03	6.08

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Revenue	708.44 Cr	830.63 Cr	998.06 Cr	1,179.82 Cr
Cost of Revenue	177.92 Cr	197.07 Cr	241.61 Cr	317.71 Cr
Gross Profit	530.52 Cr	633.57 Cr	756.45 Cr	862.11 Cr
Operating Expenses	294.39 Cr	328.82 Cr	370.16 Cr	398.77 Cr
Operating Income	236.13 Cr	304.75 Cr	386.28 Cr	463.35 Cr
EBITDA	293.05 Cr	380.56 Cr	468.71 Cr	549.46 Cr
Interest Expense	5.48 Cr	4.51 Cr	2.55 Cr	52.93 L
Pretax Income	237.52 Cr	322.01 Cr	412.56 Cr	494.55 Cr
Tax Provision	62.59 Cr	81.93 Cr	104.46 Cr	122.91 Cr
Net Income	174.93 Cr	240.09 Cr	308.10 Cr	371.64 Cr
Diluted EPS	16.72	22.95	29.45	35.52

Compounded Sales Growth

5 Years:	18.53%
1 Year:	13.70%

Compounded Profit Growth

5 Years:	28.55%
1 Year:	-16.30%

Stock Price Performance

1 Year:	-36.53%
6 Months:	-25.54%
3 Months:	-4.38%
1 Month:	-7.34%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Assets	1,312.80 Cr	1,513.98 Cr	1,700.71 Cr	2,034.25 Cr
Current Assets	632.67 Cr	727.70 Cr	896.23 Cr	1,135.24 Cr
Cash & Equivalents	66.70 L	3.50 Cr	15.14 Cr	90.45 L
Inventory	195.12 Cr	212.31 Cr	207.95 Cr	239.67 Cr
Receivables	232.17 Cr	273.76 Cr	349.61 Cr	521.65 Cr
Total Liabilities	209.57 Cr	223.98 Cr	174.06 Cr	221.53 Cr
Current Liabilities	155.17 Cr	191.84 Cr	142.16 Cr	184.06 Cr
Long Term Debt	31.25 Cr	6.24 Cr	0	0
Total Debt	62.49 Cr	31.55 Cr	9.74 Cr	2.97 Cr
Total Equity	1,103.22 Cr	1,290.00 Cr	1,526.65 Cr	1,812.72 Cr
Shares Outstanding	10.46 Cr	10.46 Cr	10.46 Cr	10.46 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Operating Cash Flow	207.47 Cr	246.00 Cr	265.47 Cr	244.52 Cr
Investing Cash Flow	-111.79 Cr	-157.95 Cr	-154.61 Cr	-159.99 Cr
Financing Cash Flow	-100.16 Cr	-85.22 Cr	-99.21 Cr	-98.77 Cr
Capital Expenditure	-155.50 Cr	-145.08 Cr	-85.69 Cr	-111.17 Cr
Free Cash Flow	51.97 Cr	100.92 Cr	179.78 Cr	133.34 Cr
Net Change in Cash	-4.48 Cr	2.83 Cr	11.64 Cr	-14.24 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Gross Margin %	74.9%	76.3%	75.8%	73.1%
Operating Margin %	33.3%	36.7%	38.7%	39.3%
Net Margin %	24.7%	28.9%	30.9%	31.5%
ROE %	15.9%	18.6%	20.2%	20.5%
ROCE %	20.4%	23.0%	24.8%	25.0%

Shareholding Pattern

Insiders

74.26%

Institutions

12.54%

Public Float

48.73%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CONCORDBIO

No recent headlines available.

CONCORDBIO · Healthcare